Press Releases in 2018

Check out the latest press releases from Novus. For direct media requests, contact us at
View Press Releases From: 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007

Bio-Techne Signs Strategic Cooperation Agreement with Micropoint Bioscience

Release Date: 
Friday, October 12, 2018 - 12:00

MINNEAPOLIS, Oct. 12, 2018 /PRNewswire/ -- Bio-Techne has entered into a strategic cooperation agreement with Micropoint Bioscience of Shenzhen, China. Chuck Kummeth, President and CEO of Bio-Techne, Yan Pingyi, Chairman of Micropoint Bioscience, and Wang Bin, Executive Vice President, Shenzhen Association of Medical Devices, all attended the meeting and signing ceremony.

Bio-Techne Scientist Presented with the CASSS CE Pharm Award

Release Date: 
Tuesday, October 2, 2018 - 12:00

MINNEAPOLIS, Oct. 2, 2018 /PRNewswire/ -- Bio-Techne is proud to announce that one of its Principal Scientists, Jiaqi Wu, Ph.D., was presented with the CE Pharm Award at this year's CE Pharm meeting, September 9-12, 2018, for his contributions to the capillary electrophoresis (CE) field.

Bio-Techne partners with BenchSci to enhance its available publication data of its commercial antibodies

Release Date: 
Monday, October 1, 2018 - 12:00

Novus Biologicals and R&D Systems announce that they will list their catalog of antibodies on BenchSci’s website to increase the amount of published antibody validation data available to researchers. BenchSci is a revolutionary data mining company that uses artificial intelligence and machine learning to gather published antibody usage data from open- and closed-access journals about commercial antibodies available for purchase on their website.

Bio-Techne Announces Cell and Gene Therapy Initiative

Release Date: 
Thursday, September 27, 2018 - 12:00

MINNEAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Bio-Techne, a global leader of research and manufacturing-grade reagents, has announced a corporate initiative to advance cell and gene therapy research and ex vivo cell processing. Through strategic acquisitions and internal scientific innovation, Bio-Techne has become uniquely positioned to provide a comprehensive, innovative, and flexible set of reagents and instrumentation across the cell and gene therapy workflow.

Bio-Techne Supports International Antibody Validation Meetings

Release Date: 
Wednesday, September 19, 2018 - 12:00

MINNEAPOLIS, Sept. 19, 2018 /PRNewswire/ -- Bio-Techne is proud to be sharing its 30+ years of industry leading expertise in antibody development and validation from its R&D Systems and Novus Biologicals brands at the 3rd International Antibody Validation Meeting on September 20-21, 2018.

Bio-Techne Fills a Need for Simple Tools to Study Glycobiology

Release Date: 
Thursday, September 6, 2018 - 12:00

MINNEAPOLIS, Sept. 6, 2018 /PRNewswire/ -- Bio-Techne researchers publish papers that promise to open the field of glycobiology to the masses.

Bio-Techne Introduces GMP Small Molecules for Stem Cell Therapy Development

Release Date: 
Wednesday, August 8, 2018 - 12:00

MINNEAPOLIS, Aug. 8, 2018 /PRNewswire/ -- Bio-Techne has introduced a new range of Tocris Bioscience-branded stem cell research compounds produced to cGMP standards, which are suitable for use as ancillary materials in the development of stem cell therapies.

Bio-Techne Introduces New Member of the Simple Western™ Family, with IR/NIR Detection Capabilities

Release Date: 
Tuesday, July 24, 2018 - 00:00

MINNEAPOLIS, July 24, 2018 /PRNewswire/ -- Bio-Techne again disrupts protein analysis technology with the introduction of the newest member of their ProteinSimple-branded Simple Western family, Jess. This evolutionary technology simplifies protein expression analysis, while speeding up time to result. Jess automates both the protein separation and immunodetection elements characteristic of traditional protein analysis techniques, eliminating many of the tedious, error-prone steps.

Bio-Techne Scales Antibody Validation Initiative Using CRISPR Gene Editing Technology Across a Broad Spectrum of Targets

Release Date: 
Tuesday, July 10, 2018 - 00:00

Knockout Validation of Antibodies Confirms Specificity and Ensures Reproducible Results

MINNEAPOLIS, July 10, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a family of brands with a unique and leading portfolio of antibody-based reagents for life science and clinical research, has been validating an extensive and growing number of antibodies using recent advances in gene editing technology.